Sign In

Pek Lum

Bringing precise medicines to patients

Pek Lum is the CEO and Founder of Auransa Inc., an AI-driven pharmaceutical startup dedicated to developing precise medications for cancer, aging-related conditions, and other disorders.

With a Ph.D. from the University of Washington, a Master of Science (M.Sc.) and Bachelor of Science (B.Sc.) from Hokkaido University, and Nihongo Gakko studies from Tokyo University of Foreign Studies, Pek Lum boasts a diverse educational background.

Prior to founding Auransa Inc., Pek Lum held advisory roles at various organizations including Sequence Bio, The Michael J. Fox Foundation for Parkinson's Research, Bayes Impact, U-BIOPRED, Clearfork Bioscience, and served in leadership positions at Ayasdi, iPierian, and Rosetta/Merck.

Pek Lum and the team at Auransa Inc. comprise seasoned professionals from drug development, data science, biology, and chemistry fields with a collective objective of creating treatments to combat severe human illnesses and alleviate suffering.

Highlights

Oct 20 · linkedin

I wanted to share this Endpoints News article which mentions Auransa’s lead clinical program, AU-409, now in Phase 1 clinical trials for liver cancer. First, thank you to Andrew Dunn for keeping a watchful eye on this space, and following our work at Auransa. Second, while it’s tempting to lump all the AI drug discovery companies together, Auransa is very different.

At the height of AI usefulness is the prediction of a completely new mechanism or target. At Auransa, we first use AI/ML to make sense of complex, heterogeneous human disease biological data, before working on molecules. Most AI companies in this space work on the second kind of approach; developing a new class of drugs against a target. 

AU-409 was discovered by studying the genomic signatures of over a thousand liver tumors to understand their molecular heterogeneity. Only after that did we do compound predictions that eventually led to AU-409. The molecule was designed with quality-of-life for liver cancer patients in mind; aiming for superior tolerability and excellent liver pharmacokinetics in an oral pill. AU-409 is a differentiated molecule from other drugs for liver cancer in-market, with a novel MOA that when inhibited, is predicted to put a damper on liver cancer. We are excited for this novel mechanism as it moves through Phase 1 study.

As a trained biologist, I believe it’s so important that we direct AI to biology first, on molecular data derived from abundant, heterogenous human disease tissue data. And that those AI companies that understand biology first, and design AI discovery programs from there, will have a better chance at meaningful clinical progress.

Mar 23 · linkedin

Our AI-drug just entered the clinic! Super excited to announce our close collaboration with USC Norris Cancer. This is the beginning of our broader collaboration. Many more drugs to come! https://lnkd.in/eFWwAVKW #drugdevelopment #collaboration #ai #artificialintelligence

Pek Lum
Add to my network

Location

San Francisco Bay Area